Trial Profile
A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NICE Salvage
- 10 Sep 2019 Primary endpoint has not been met. (Progression Free Survival)
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.